A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease

Figure 6

Molecular models of binding of bioactive compounds to the core targets. (a) MOL000006 to MAPK8; (b) MOL001790 to EGFR; (c) MOL005169 to AKT1; (d) MOL001790 to SRC; (e) MOL000006 to ESR1; (f) MOL005209 to RELA; (g) MOL005188 to RAC1; (h) MOL000006 to IGF1R; (i) MOL001790 to PIK3R1.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)